ArticleJournal of experimental & clinical cancer research : CR2026
DCLK1 regulates stemness and IL-6/STAT3-dependent metastatic niche formation in chemoresistant ovarian cancer.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMetastasis is the leading cause of cancer-related mortality. In ovarian cancer, dissemination within the peritoneal cavity is the primary driver of patient death, underscoring a critical need to define the molecular mechanisms that initiate metastatic seeding and remodel the peritoneal microenvironment. Stem-like tumor cell programs are increasingly recognized as central to metastatic competence, yet the regulators linking tumor stemness to microenvironmental reprogramming remain poorly defined. Doublecortin-like kinase 1 (DCLK1), a serine/threonine kinase associated with tumor stemness, has been implicated in cancer progression, but its role in ovarian cancer metastasis is not fully understood.
methodsWe employed genetic loss-of-function approaches to investigate the role of DCLK1 in ovarian cancer metastasis using in vivo intraperitoneal dissemination models. Metastatic burden and overall survival were assessed following DCLK1 depletion. DCLK1 expression was analyzed across patient-derived ascites cultures established from primary and recurrent ovarian cancer patients and correlated with markers of metastasis-initiating cells. Functional assays were used to assess tumor cell adhesion, mesothelial clearance, stemness features and mesothelial-to-mesenchymal transition. Targeted transcriptomic and secretome analyses identified DCLK1-regulated cytokine programs. Paracrine signaling to mesothelial cells was evaluated using pharmacologic inhibition of IL-6 receptor and downstream JAK-STAT signaling.
resultsGenetic loss of DCLK1 significantly reduced intraperitoneal metastatic burden and prolonged overall survival in vivo. DCLK1 expression correlated strongly with established markers of stem-like, metastasis-initiating tumor cells across the patient-derived ascites cultures. Mechanistically, DCLK1 promoted early metastatic colonization by enhancing tumor cell adhesion, mesothelial clearance, and mesothelial-to-mesenchymal transition. Transcriptomic and secretome profiling identified interleukin-6 (IL-6) as a key downstream effector of DCLK1, with DCLK1 depletion leading to a marked reduction in IL-6 expression and secretion. Tumor-derived IL-6 activated JAK-STAT signaling in mesothelial cells, promoting mesothelial migration and a permissive metastatic niche; these effects were reversed by pharmacologic blockade of IL-6 receptor signaling.
conclusionsThese findings position DCLK1 as a central molecular mediator linking tumor-intrinsic stemness to microenvironmental reprogramming that primes the peritoneal niche for metastatic progression. Targeting DCLK1 or downstream IL-6/JAK-STAT signaling may therefore offer a rational strategy to disrupt metastatic dissemination in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.